The story of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial introduction generated substantial profits, the end of its patent opened the avenue to off-brand https://bookmarkcitizen.com/story21625977/the-copyright-and-pharma-a-volatile-investment